Darunavir-d9 is intended for use as an internal standard for the quantification of darunavir (Item Nos. 15866 | 31083) by GC- or LC-MS. Darunavir is an HIV-1 protease inhibitor. It is active against HIV-1LAI in MT-2 cells (IC50 = 3 nM) with a cytotoxic concentration (CC50) of 74.4 μM. Darunavir is also active against wild-type and multidrug-resistant clinical isolates of HIV-1 in phytohemagglutinin-activated peripheral blood mononuclear cells (PHA-PBMCs; IC50s = 3 and 3-29 nM, respectively). It inhibits cell-free diffusion and cell-to-cell spread of HIV-1 in Jurkat cell populations (IC50s = 2.5 and 2.8 nM, respectively). Formulations containing darunavir have been used in combination therapy for the treatment of HIV.
Off-White Amorphous Solid
Second generation HIV-1-protease inhibitor; structurally similar to amprenavir. Antiviral. It is a COVID19-related research product.
Darunavir-D9 can be intended for use as an internal standard for the quantification of Darunavir by GC- or LC-mass spectrometry.
Darunavir-D9 can be used as second generation HIV-1-protease inhibitor; structurally similar to amprenavir.
